Celox-A™, the new applicator for penetrating trauma wounds has now obtained a class 3 CE Mark approval allowing use in Europe.
MedTrade, Crewe, UK is proud to announce the European launch at Medica, Dusseldorf (19th -22nd Nov 08) of Celox-A.
Penetrating wounds like shrapnel or knife wounds are very difficult to treat. They can often be [...]

Popularity: 3% [?]

New analytical and R&D laboratories to expand the research and development efforts for controlled release and other technically difficult generic pharmaceutical products opened in Actavis South Atlantic, a United States division of the international generic pharmaceutical company Actavis.
The labs have been expanded by about 300 sq meters and the new R&D labs have been expanded [...]

Popularity: 5% [?]

Russell Sabella, a former Senior Sales Representative with GlaxoSmithKline in the Bronx, NY has penned down an e-book on the ways to earn a good career in the pharmaceutical industry. The author’s career with GlaxoSmithKline stemmed from April 2004 until June of 2008.
This e-book is a funny, witty and sometimes off the wall memoir which [...]

Popularity: 4% [?]

Actavis Group employees from diverse departments from all over the world will be present at this year’s annual CPhI conference, held in Frankfurt, Germany, 30 September to 2 October.
Actavis’ third party sales division, Medis, had its own stand at the CPhI exhibition for 8 years, but shared the floor with Actavis Group last year for [...]

Popularity: 9% [?]

Actavis, the international generic pharmaceuticals company, recently launched Bicalutamide tablets in the UK, Germany and France. Acuavis Bicalutamide is the first generic version of the oncology drug to be made available in the three markets.
Actavis has launched a generic drug for prostate cancer, Bicalutamide, in the UK, France and Germany.
Bicalutamide, the generic version of AstraZeneca’s [...]

Popularity: 13% [?]

Generic pharmaceutical firm Actavis has significantly increased its capability in producing oncology pharmaceuticals with the purchase of a Pfizer manufacturing site.
Reykjavik (eNewsWire) 28 January 2008 - Actavis, the international generic pharmaceuticals company, has signed an agreement with Pfizer to acquire a manufacturing site specialising in oncology products.
The site, which covers an area of 300,000 square [...]

Popularity: 10% [?]